lucar-g39d
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 11, 2024 (NCT06295549)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- B-lymphocyte antigen CD20Immunity, passive
MS4A1 immunity, passive
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06395870 | Phase 1 | May 9, 2024 | GenScript, Tianjin Medical University |
| NCT06295549 | Phase 1 | Apr 11, 2024 | GenScript, Nanjing Medical University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GenScript | For profit | 2 | 0 | 1 | 2024 |
| Nanjing Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Tianjin Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1